Abstract 1941P
Background
Epithelioid sarcoma (ES) is a rare and aggressive subtype of soft-tissue sarcoma. The loss of INI1 expression which leads to oncogenic dependence on the transcriptional repressor EZH2 has been observed in over 90% of ES. There remains a need for effective and safe treatment options for patients (pts) with advanced ES. We investigated the efficacy and safety of SHR-2554, an oral selective EZH2 inhibitor, in pts with refractory ES.
Methods
Pts were eligible if they were aged 12 years or older with histologically confirmed advanced or metastatic ES. Other key inclusion criteria: the presence of measurable disease according to RECIST 1.1; an ECOG performance status of 0-1; progressive disease after at least one line of adriamycin containing chemotherapy; documented loss of SMARCB1 (INI1) alterations or the upregulated mRNA level of EZH2. Pts received SHR2554 (350 mg, bid, po) until disease progression or unacceptable toxicity. The primary endpoint was progression-free rate at 12 weeks. A Simon two-stage design was applied. Success at stage 1, which would enroll 9 pts, required ≥3 pts remaining progression-free at 12 weeks.
Results
Between Jul 2021 and Dec 2022, a total of 9 pts were enrolled and received SHR-2554. The median age was 44 years and 33.3% were males. 5 (55.6%) pts had received previous immunotherapy targeting PD-1/L1 and 4 (44.4%) pts had received previous antiangiogenesis therapy. The median line of previous treatment was 2 (range 1-4). Loss of INI1 was confirmed in 6 (66.7%) pts. 5 (55.6%) pts remained progression-free at 12 weeks, which allowing to move on to stage 2. Based on investigator assessments, one (11.1%) of 9 pts had a confirmed partial response at data cutoff. The median progression-free survival was 3.8 months (95% CI: 1.2–NA). Adverse events (AEs) were generally mild. The most common treatment-related AEs were anaemia (3, 33.3%). No serious treatment-related AEs were observed.
Conclusions
SHR-2554 showed promising efficacy and an acceptable safety profile in pts with refractory ES, warranting further investigation.
Clinical trial identification
ChiCTR2100046099.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1971P - Metastatic osteosarcoma, patterns of care and outcomes of patients in a real-life setting: The Metabone national observational study
Presenter: Mathilde Reich
Session: Poster session 15
1972P - Molecular mechanism study of recurrence/metastasis for Enneking IIb osteosarcoma
Presenter: Junqiang Yin
Session: Poster session 15
1975P - Systemic therapy for KIT/PDGFRA wild-type GIST
Presenter: Mehdi Brahmi
Session: Poster session 15
1976P - Financial difficulties experienced by gastrointestinal stromal tumor (GIST) patients in the Netherlands: Data from a cross-sectional multicenter study
Presenter: Deborah van de Wal
Session: Poster session 15
1977P - A registry-based analysis of the projected genomic landscape among unclassified KIT/PDGFRA wildtype mutations in patients with gastrointestinal stromal tumors
Presenter: Jerry Call
Session: Poster session 15
1978P - Identification of SDH-deficient GIST increases after the implementation of diagnostic algorithm in Life Raft Group (LRG) patient registry data
Presenter: Denisse Evans
Session: Poster session 15
1979P - phase I trial of pembrolizumab in HIV-associated Kaposi sarcoma (KS)
Presenter: Kathryn Lurain
Session: Poster session 15
1980P - Artificial intelligence analysis shows enhanced CCNG1 expression in sarcoma tumors, a novel biomarker for DeltaRex-G tumor targeted retrovector encoding a CCNG1 inhibitor gene
Presenter: Sant Chawla
Session: Poster session 15
1981P - Histopathological diagnostic discrepancies in bone and soft tissue tumors referred to a specialist sarcoma center and its clinical impact
Presenter: Akira Kawai
Session: Poster session 15